Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mortality in antiepileptic drug development programs.

J A Racoosin1, J Feeney, G Burkhart

  • 1Division of Neuropharmacological Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD 20857, USA. racoosinj@cder.fda.gov

Neurology
|February 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antimicrobial coated intracortical probes reduce invading microbe abundance and subsequent neuroinflammation.

Biomaterials·2025
Same author

Hair cortisol as a risk marker for increased depressive symptoms among older adults during the COVID-19 pandemic.

Psychoneuroendocrinology·2022
Same author

Change in perceived stress and 2-year change in cognitive function among older adults: The Irish Longitudinal Study on Ageing.

Stress and health : journal of the International Society for the Investigation of Stress·2018
Same author

Non-Dietary Correlates and Determinants of Plasma Lutein and Zeaxanthin Concentrations in the Irish Population.

The journal of nutrition, health & aging·2017
Same author

CT Colonography in the Detection of Colorectal Cancer in Ireland; Economical Considerations and the Potential for Centralisation of Service Provision.

Irish medical journal·2017
Same author

Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia.

Endocrinology, diabetes & metabolism case reports·2016
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Patients with epilepsy in clinical trials experienced high mortality, with most deaths linked to epilepsy. Sudden unexplained death risk appears higher in add-on therapy trials, suggesting disease severity is a key factor.

Area of Science:

  • Neurology
  • Clinical Pharmacology
  • Public Health

Background:

  • Pooled New Drug Application (NDA) data offers insights into rare event incidence and risk factors.
  • Analysis focuses on epilepsy patients in clinical trials for antiepileptic drugs (AEDs).

Purpose of the Study:

  • To determine mortality incidence and causes in epilepsy patients during AED clinical trials.
  • To investigate sudden unexplained death (SUD) incidence and associated risk factors in this population.

Main Methods:

  • Utilized exposure data and death narratives from NDAs of five AEDs.
  • Classified deaths using expert panel criteria (1993 Burroughs-Wellcome) into sudden unexplained, accidental, or other causes.
  • Calculated mortality rates and analyzed add-on versus monotherapy initiation trials separately.

Related Experiment Videos

Main Results:

  • In add-on trials (9,144 patients), all-cause and SUD mortality rates were 9.1 and 3.8 per 1,000 person-years, respectively.
  • Epilepsy accounted for 65% of all deaths; only age was linked to SUD incidence.
  • In monotherapy trials (1,293 patients), rates were 7.1 (all-cause) and 0 (SUD) per 1,000 person-years.

Conclusions:

  • A significant portion of deaths in the add-on cohort were epilepsy-related.
  • Sudden death rates in the add-on cohort are at the higher end of reported ranges for epilepsy patients.
  • Higher SUD mortality in add-on versus monotherapy trials suggests disease severity is a primary risk determinant.